Clinical Trial Update: PD-1 Knockout Engineered T Cells for Metastatic Non-small Cell Lung Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating PD-1 knockout engineered T cells in metastatic non-small cell lung cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non Small Cell Lung Cancer

Drugs mentioned

• PD-1 Knockout Engineered T Cells

Snippet

Sponsor: Sichuan University | Conditions: Metastatic Non-small Cell Lung Cancer | Phase 1 | Status: COMPLETED | Results posted: 2020-12-21